Environmental concentrations of Hexachlorobenzene reduce the efficacy of doxorubicin and paclitaxel treatment on triple negative breast cancer cells

YAMILA SÁNCHEZ; ABIGAIL VÁSQUEZ; CATALINA GABINO ROLANDELLI; ANDREA RANDI; ALEJANDRO ESPAÑOL

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencias; 2022

Sociedad Argentina de Investigación Clínica

The contamination by hexachlorobenzene (HCB) is a relevant problem since it has been detected in human serum and breast milk. It activates Aryl hydrocarbon Receptor (AhR), which is associated with tumor development. HCB induces proliferation in different types of breast tumor cells, but it is unknown its role in antitumor breast therapy. Triple negative (TN) subtype constitutes 10% of breast tumors and present a bad prognosis due to the lack of specific therapeutic targets. They are treated with chemotherapeutic drugs such as paclitaxel (PX) and doxorubicin (DX).The aim of this work was to determine if HCB modulates the antitumor effect of PX and DX in the human TN breast cancer cell line MDA-MB231. We demonstrated by Western blot assays that these cells express AhR, and by MTT assays that HCB does not modify their viability in the range of 10-12M-10-5M (p>0.05).These cells are sensitive to PX and DX in a concentration-dependent manner (CI50PX:1.34x10-3M CI50DX:6.1x10-10M). PX (10-7M) exerts its effect by modulating Ras(89.8±5.5%